TY - JOUR

T1 - Screening for affinity ligands for biopurification

AU - St. Hilaire, Phaedria M.

AU - Meldal, M.

PY - 2006/10

Y1 - 2006/10

N2 - The worldwide market for biopharmaceuticals and the number of new pro tein drugs are rapidly increasing. For every new drug a new purification process must be developed. For some drugs this can be achieved by modify ing the process parameters used in an existing process whereas for other drugs a whole new process must be developed. This can be a challenging and very costly process, which in the worst case delays the product launch. The problem can be largely overcome by implementing affinity chromatography. However, there is a need for affinity ligands for purifying non-immunoglob ulins. We present here an overview of technologies and suppliers within the field of development of affinity chromatography media.

AB - The worldwide market for biopharmaceuticals and the number of new pro tein drugs are rapidly increasing. For every new drug a new purification process must be developed. For some drugs this can be achieved by modify ing the process parameters used in an existing process whereas for other drugs a whole new process must be developed. This can be a challenging and very costly process, which in the worst case delays the product launch. The problem can be largely overcome by implementing affinity chromatography. However, there is a need for affinity ligands for purifying non-immunoglob ulins. We present here an overview of technologies and suppliers within the field of development of affinity chromatography media.

UR - http://www.scopus.com/inward/record.url?scp=35948982594&partnerID=8YFLogxK

M3 - Review

AN - SCOPUS:35948982594

VL - 18

SP - 12

EP - 16

JO - Bio Tech International

JF - Bio Tech International

IS - 5

ER -